Research and Development in Nanotechnology (NAICS 541713): A U.S. Industry Primer

1. Overview

Nanotechnology is the science of building and measuring matter at the nanoscale — roughly 1 to 100 nanometers (nm), where a human hair is about 80,000–100,000 nm wide.[1] At that scale materials behave differently: gold turns catalytic, carbon becomes stronger than steel, and particles can slip through cell membranes. It is a platform technology, not a single end market.

The firms in North American Industry Classification System (NAICS) code 541713 are the laboratories and technical-services companies whose primary business is conducting nanotechnology research and experimental development — inventing new nanoscale processes, materials, prototypes, and measurement methods that other industries then manufacture and sell.[1] This is not a product-selling industry in the ordinary sense. It is an R&D-for-hire and invention business: owners make money from research contracts, government grants, milestone payments from corporate partners, and licensing the patents that come out of the lab. The output is knowledge and intellectual property (IP), not usually finished goods.

Why it matters to an investor: nanotechnology sits upstream of some of the largest growth stories in the economy — advanced semiconductors, artificial-intelligence (AI) hardware, electric-vehicle batteries, messenger-RNA (mRNA) drug delivery, quantum-dot displays, water filtration, and defense materials. But it is a hard place to invest directly. Public pure-plays are scarce and mostly speculative micro-caps; the real activity lives in private startups, university spinouts, corporate in-house labs, and federal research programs.

• Public-market route: the most credible exposure is indirect — the semiconductor-equipment, metrology, scientific-instrument, and advanced-materials companies that supply and commercialize what the labs invent (the "picks and shovels"). Direct nano-branded pure-plays are a handful of small, often unprofitable names.
• Private route: venture and growth capital, corporate partnerships, contract R&D, university technology transfer, and licensing. The typical exit is acquisition by a strategic buyer or a royalty stream, not an initial public offering (IPO).

The National Nanotechnology Initiative (NNI) — the interagency program that has coordinated U.S. nanotech R&D since 2001 — remains active; the President's fiscal-year (FY) 2026 budget requested about $1.45 billion for NNI research and infrastructure across 10 agencies. That is a request, not an enacted appropriation.[2]

2. What it is and how it's structured

In scope (541713): establishments primarily engaged in nanoscale research and experimental development — into materials, devices, coatings, sensors, electronics, energy systems, biomedical applications, and manufacturing processes — whose work may yield a new process, prototype, patent, or measurement method for other industries to reproduce and use.[1] Typical occupants: independent and contract research labs, nanomaterial-development startups, university-affiliated spinouts, and the R&D arms of firms that self-identify as nanotechnology companies.

What it excludes — this matters, because R&D is notoriously hard to classify and several adjacent codes carve off big chunks of "nano-adjacent" work:

• 541714 — R&D in Biotechnology (except nanobiotechnology): DNA technologies, protein engineering, other biotech lab work.[3]
• 541715 — R&D in the Physical, Engineering, and Life Sciences (except nanotechnology and biotechnology): the large catch-all for most other lab science.[3]
• 541380 — Testing Laboratories; 541420 — Industrial Design Services; 621511 — Medical Laboratories; 813212 — health-research fundraising organizations: related services that are not nanoscale R&D.[1]
• Manufacturing codes: a company that actually produces and sells nanomaterials or nano-enabled devices at scale is classified by that product (chemical, semiconductor, or battery manufacturing), not here — once manufacturing becomes the principal activity, the firm leaves 541713.
• Universities and colleges (educational services) and federal or national laboratories (public administration) — even though they perform an enormous share of U.S. nanoscience.

Together, 541713–541715 replaced the older 2012 NAICS R&D codes 541711 (biotech) and 541712 (physical/engineering/life sciences); nanotechnology was pulled out into its own code in the 2017 revision.[3]

Ownership mix: overwhelmingly private, and the federal statistics do not publish a public-versus-private split. Qualitatively the ecosystem spans a long tail of small, privately held labs and venture-backed startups; a modest number of mid-size contract research organizations; the captive R&D units of larger corporations; and public equipment and instrument suppliers downstream. HRL Laboratories illustrates the corporate-lab model — a private company jointly owned by Boeing and General Motors that conducts R&D for its owners.[5] The Small Business Administration (SBA) sets the small-business size standard for this code at 1,000 employees — high, reflecting that even the larger independent labs are not giants, and relevant to federal-contracting eligibility.[4]

3. How big it is

Federal business statistics for standalone nanotech-R&D establishments:

These are snapshots from different federal programs and years and should not be added together: the 2023 County Business Patterns (CBP) figures use the 2017 NAICS basis, while the 2022 Economic Census uses the 2022 NAICS basis.[8] Receipts is the revenue measure available for this code; the Census does not publish a separate value-added or export figure here.

Concentration is low. The four largest firms account for 38.6% of receipts (the four-firm concentration ratio, CR4), the top eight for 57%, the top twenty for 73%, and the top fifty for 83.5%; the Herfindahl-Hirschman Index (HHI, a standard concentration gauge where under 1,500 is "unconcentrated") is just 551.[7] In plain terms: no dominant player, a crowded field, and a fat tail of small labs.

The undercount caveat is large and runs in both directions. These figures capture only establishments whose primary activity is nanotech R&D, and CBP by construction excludes the self-employed, businesses without employees, and most government workers, and can miss very small operators.[8] They therefore miss the bulk of U.S. nanoscience, which is performed inside universities, federal and national labs, and the in-house research divisions of big chemical, pharmaceutical, and semiconductor companies — none classified in 541713. As a scale check, cumulative federal funding through the NNI totals nearly $47 billion since 2001, none of it captured as "receipts" in this code.[2] At the same time, the boundary between "nanotechnology" R&D and ordinary materials or biotech research is genuinely fuzzy. Treat the $44.5 billion as the independent, for-hire slice of a much larger national research effort, not the whole thing.

4. The investable universe

There is no large, profitable public company whose sole business is nanotech R&D — the honest answer is that direct public plays are few, small, and speculative, while the most credible public exposure is to the firms selling the tools and materials that make nanoscale research and manufacturing possible. The names below should not be described as 541713 companies; they are downstream suppliers and commercialization beneficiaries.

Public companies

Camtek (CAMT) is a further inspection/metrology name. Diversified materials & chemicals giants — BASF, DuPont (NYSE: DD), and Merck KGaA — embed nanomaterials in coatings, electronics, and consumer goods, where nanotech is one growth driver inside a large, cash-generating business.[9]

Private companies and owners (the deepest pool of genuine nanotech R&D)

• Sila Nanotechnologies: venture-backed; commercializing silicon-based battery anode materials; investors include venture funds, pension capital, and strategic automotive/electronics partners.[19]
• Group14 Technologies: silicon-anode battery material; has raised over $1.2 billion.[17]
• Forge Nano: ALD coatings for semiconductor equipment and battery materials; announced in 2026 that it expected to list via a SPAC (special-purpose acquisition company) merger in the second half of 2026 — verify status before acting.[18]
• Nano-C: advanced materials — fullerenes, single-wall carbon nanotubes, and electronic materials for solar, semiconductors, and batteries.[20]
• American Elements: advanced-materials supplier with materials-science R&D serving corporate, government, and academic customers.[21]

U.S. carbon-nanotube companies alone have drawn roughly $165 million in cumulative venture and private-equity funding across ~31 funded firms.[17] Important non-company infrastructure — often more decisive to early commercialization than its ownership implies — includes the National Institute of Standards and Technology's (NIST) Center for Nanoscale Science and Technology, National Science Foundation (NSF)-supported university nanofabs, and public-private centers such as Albany NanoTech.[22][23]

Bottom line for the reader: targeted public exposure means micro-caps carrying real dilution and survival risk; broader, safer exposure comes from the diversified materials and semiconductor-equipment names, or from private-market vehicles.

5. How the money works

Owners in this industry monetize invention and lab capacity, and revenue is often lumpy. The main streams:

• Government research contracts and grants. Federal agencies — the National Institutes of Health (NIH), National Science Foundation (NSF), Department of Energy (DOE), Department of Defense (DOD), and NIST — fund nanotech R&D through the NNI.[2] For small firms, SBIR/STTR grants (Small Business Innovation Research / Small Business Technology Transfer) are a crucial source of non-dilutive cash — money that funds work without selling equity.
• Corporate sponsored and contract research. Semiconductor, chemical, automotive, aerospace, and pharma companies pay labs to solve specific problems, often cost-plus or fixed-fee; customer concentration, milestone payments, and exclusivity shape the economics.
• Shared research infrastructure. Open-access nanofabs and characterization centers earn tool-utilization and consortium fees, frequently supported by public subsidy.
• Intellectual-property licensing and royalties. A patented nanomaterial or process can throw off royalties for years — the highest-margin outcome, but slow to arrive, and dependent on patent quality, remaining patent life, and freedom to operate.
• Milestone and collaboration payments as a project hits technical targets.
• Material and process commercialization for the hybrids that both invent and produce (a nanoparticle sold by the kilogram into cosmetics, coatings, or batteries), where yield, throughput, defect rate, qualification time, and scale-up capital dominate.

Cost structure and the metrics that matter. This is a high-fixed-cost, talent-heavy business — PhD scientists (average pay near $154,000[6]) plus expensive capital equipment: cleanrooms, electron microscopes, and characterization instruments. Salaries and facilities are relatively fixed while project revenue arrives in milestones, so cash flow is uneven. The gauges that fit this industry:

• Billable utilization of scientists and instrument time (for contract labs).
• Contract backlog and grant win-rate — forward revenue visibility for services-oriented firms.
• Cash runway versus burn rate — for the many pre-revenue startups, the single most important number.
• Scale-up yield and cost-per-kilogram trends — whether a lab process survives contact with industrial-scale manufacturing (many do not).

For the public equipment and instrument suppliers, the more useful metrics are bookings, backlog, recurring installed-base/service revenue, gross margin, customer concentration, and exposure to the semiconductor capital-spending cycle. The defining financial reality for the R&D firms themselves is a long, cash-hungry gap between a promising lab result and a paying product — the so-called "valley of death." Many firms never cross it.

6. What drives demand

• Advanced computing and semiconductors. Smaller transistors, three-dimensional structures, advanced packaging, extreme-ultraviolet (EUV) lithography, and AI hardware all demand tighter deposition, etch, inspection, and measurement at the nanoscale — currently the strongest single pull on the industry.[28]
• Federal R&D budgets. The NNI is the demand backbone for the grant-funded segment. The President's FY2025 budget requested a record $2.2 billion across 12 agencies; the FY2026 request fell to $1.45 billion across 10 agencies.[2][24][25] A shrinking request is a forward-looking warning sign for firms that lean on government funding.
• Defense and supply-chain security. Nanomaterials, sensors, advanced electronics, and lightweight structures are national-security technologies; federal programs and export controls increasingly emphasize domestic capability.[2]
• Energy storage and generation. Silicon-anode and solid-state battery chemistry, catalysts, membranes, and solar materials are major destinations for nanomaterial R&D and venture money.[17][19]
• Healthcare and drug delivery. The mRNA COVID-19 vaccines validated lipid nanoparticles (LNPs) as a delivery platform; by third-party market-research estimates (not federal data) the nanotechnology drug-delivery market was worth roughly $104 billion in 2024, with North America dominating LNP demand.[26][27]
• Water and environmental applications. Nanoporous membranes, sensors, catalysts, and remediation media offer potential performance gains.[28]
• Research infrastructure and venture cycles. Open-access nanofabs lower the cost of early experimentation, while corporate R&D budgets and venture-funding availability set the pace of startup formation.[23]

7. Regulation

There is no single "nanotechnology law." Nanomaterials are regulated product-by-product under existing frameworks; the practical diligence question is not "Is it nano?" but "What is the material, what does it do, who uses it, and where does it go?"

• EPA and the Toxic Substances Control Act (TSCA). Under a TSCA Section 8(a) rule finalized in 2017, companies that manufacture, import, or process certain chemical substances as nanoscale materials (1–100 nm) must report chemical identity, production volume, methods, uses, exposure, and available health-and-safety data to the Environmental Protection Agency (EPA). Genuinely new nanomaterials also face pre-manufacture new-chemical review.[29]
• FDA. The Food and Drug Administration (FDA) has no single legal definition of nanotechnology and no separate nano statute; it regulates nano-enabled drugs, devices, foods, and cosmetics through its normal, product-specific pathways guided by nanotechnology guidance documents.[30]
• Worker safety. The Occupational Safety and Health Administration (OSHA) addresses engineered-nanomaterial exposure through existing chemical, laboratory, respiratory-protection, hazard-communication, and general-duty requirements; the National Institute for Occupational Safety and Health (NIOSH) publishes recommended exposure limits for materials such as titanium dioxide and carbon nanotubes.[31]
• Export controls. The Bureau of Industry and Security's (BIS) Export Administration Regulations (EAR) restrict certain advanced semiconductor equipment, software, technology, end uses, and destinations. Nanotechnology is not automatically controlled, but dual-use semiconductor and defense technologies can be; work embedded in a defense article may also implicate the International Traffic in Arms Regulations (ITAR).[32]
• Advertising claims and grant compliance. Health, performance, and "green" claims must be truthful and evidence-based (overstated "nano" claims invite litigation), and firms living on federal funding carry the associated reporting and audit burdens.

The forward-looking regulatory question is toxicity: as more nanomaterials scale into consumer and industrial use, health and environmental scrutiny — and compliance cost — is likely to rise.

8. Competitive dynamics and consolidation

The industry is fragmented and unconcentrated (top-four share 38.6%, HHI 551[7]) — a crowded field of small labs and startups rather than a few dominant firms. The concentration figures measure employer-firm receipts, not control of the whole nanotechnology ecosystem. Competition splits along a few lines:

• Diversified materials giants (BASF, DuPont) with the balance sheets to scale nanomaterials into real products.
• Instrument, metrology, and equipment firms (Applied Materials, Lam Research, KLA, Onto Innovation, Bruker, Veeco) that supply the tools everyone else needs.
• Specialist startups and university spinouts racing to prove a single material or process before the cash runs out.
• Lower-cost overseas producers — notably Chinese and Korean carbon-nanotube and battery-material makers (e.g., Cnano, LG Chem) — that have driven nanotube prices down 15–25% as they scaled to hundreds of tonnes per year, squeezing Western commodity-nanomaterial economics.[17]

Consolidation runs through acquisition, not merger of equals. The standard endgame for a successful small nanotech firm is to be bought by a strategic acquirer in chemicals, semiconductors, or pharma that wants the team and the patents — or to license its IP and collect royalties. It concentrates most plausibly around specialized metrology, ALD/deposition and process-control tools, proprietary coatings, defensible university-spinout patents, and cleared contract-R&D firms. Low concentration creates acquisition potential but does not guarantee pricing power: customers keep leverage when technologies are early-stage, qualification is incomplete, or government and university facilities offer alternatives. IPOs are the exception.

9. Risks

• Commercialization risk (the "valley of death"). Many nanomaterials work beautifully in the lab and never survive industrial scale-up, yield and reliability requirements, or customer qualification.
• Funding-cycle dependence. Grant-reliant firms are exposed to federal budget swings — the FY2026 NNI request fell sharply from FY2025.[24][25]
• Capital intensity and dilution. Pre-revenue micro-caps and private companies burn cash and repeatedly raise equity; dilution and outright failure are common.
• Cyclicality. Semiconductor-equipment and advanced-materials suppliers are exposed to fab capital spending, inventory cycles, and export restrictions.
• Customer concentration. A single strategic customer may fund development, then delay, internalize, or abandon the program.
• Toxicity, health, and environmental liability. Some engineered nanomaterials (certain carbon nanotubes) raise safety concerns that could bring tighter regulation or litigation.
• Geopolitical and foreign-competition risk. Export controls can close markets and restrict collaboration; overseas producers pressure commodity-nanomaterial pricing.
• Intellectual-property risk. Patents may be narrow, hard to enforce, or vulnerable to competing approaches and trade-secret leakage.
• End-market concentration. Demand clusters in a few sectors (semiconductors, batteries) that are themselves cyclical.
• Data and "nano-washing" risk. Federal employer statistics omit parts of the government, university, and self-employed ecosystem, and some companies use "nano" in marketing without material revenue or defensible nanoscale technology.

10. How to invest and the outlook

Public-market routes. Treat the sector as a group of proxies, not a discrete industry.

• Direct pure-plays are limited to small and micro-cap names (Nanophase/NANX, Nanoco/NANO, Applied DNA/APDN, Nano-X/NNOX) — high risk, frequently unprofitable, thinly traded. Speculative.[9][10]
• Indirect "picks and shovels" is the more prudent path: semiconductor-equipment and metrology makers (Applied Materials/AMAT, Lam Research/LRCX, KLA/KLAC, Onto Innovation/ONTO, Bruker/BRKR, Veeco/VECO) and diversified materials leaders (BASF, DuPont/DD, Merck KGaA), where nanotech is one growth driver inside a real business.[11][12][13][14][15][16] Compare them on nano-specific revenue exposure, recurring service/consumables revenue, backlog and customer concentration, research spending and patent quality, cash generation through the semiconductor cycle, and exposure to China, defense, and export controls.

Private-market routes. Direct equity, venture funds, corporate-venture partnerships, university technology transfer, or contract-R&D platforms — the deepest pool of genuine nanotech R&D exposure, but illiquid and long-dated (recent flagship raises include Sila and Group14's $1.2 billion for battery material[17][19]). Core diligence: IP ownership, freedom to operate, customer validation, government rights, scale-up capital, and the path from prototype to repeat orders. The realistic return driver is an acquisition or a licensing royalty, not a near-term IPO.

Forward-looking judgment. The base case is continued long-term demand for nanotechnology-enabled tools and materials, led by advanced semiconductors and AI infrastructure — the strongest current tailwind — plus defense, energy storage, healthcare, and environmental applications; battery and drug-delivery R&D remain well funded by private capital.[17][26] The clearest headwind is the declining federal NNI budget request, from a record $2.2 billion (FY2025) to $1.45 billion (FY2026), which tightens the grant lifeline many small U.S. nanotech labs depend on.[24][25] Net judgment: end-market demand for nano-enabled products is robust and broadening, but the standalone R&D-services industry remains fragmented, cash-hungry, and hard to own cleanly in public markets. The likely winners are firms that convert scientific capability into repeatable manufacturing and recurring service or licensing revenue; the highest upside — and the highest failure rate — remains among private companies commercializing new materials, devices, and processes. Best approached indirectly through the "picks and shovels," or through private capital with a long horizon and tolerance for failure.

---

Sources

1. U.S. Census Bureau, "2022 NAICS: 541713 — Research and Development in Nanotechnology" (definition and adjacent codes). https://www.census.gov/naics/?input=541713&year=2022
2. National Nanotechnology Coordination Office, "Supplement to the President's 2026 Budget" (FY2026 request ~$1.45 billion across 10 agencies; cumulative NNI funding nearly $47 billion since 2001), 2026. https://www.nano.gov/2026budgetsupplement/
3. U.S. Bureau of Labor Statistics, "NAICS in the Current Employment Statistics Program" (2017 NAICS: 541711/541712 split into 541713–541715), 2017. https://www.bls.gov/ces/naics/naics-2017.htm
4. U.S. Small Business Administration, "Table of Small Business Size Standards" (NAICS 541713 = 1,000 employees), 2023. https://www.sba.gov/document/support-table-size-standards
5. HRL Laboratories, "About HRL" (jointly owned by Boeing and General Motors), 2026. https://www.hrl.com/about
6. U.S. Census Bureau, County Business Patterns, NAICS 541713 (establishments, employment, Q1 and annual payroll), 2023. https://www.census.gov/programs-surveys/cbp.html
7. U.S. Census Bureau, 2022 Economic Census — Concentration by Largest Firms, NAICS 541713 (receipts, firm count, CR4/CR8/CR20/CR50, HHI), 2022. https://www.census.gov/programs-surveys/economic-census.html
8. U.S. Census Bureau, "County Business Patterns Methodology" (coverage exclusions; 2017 vs 2022 NAICS basis). https://www.census.gov/programs-surveys/cbp/technical-documentation/methodology.html
9. Research and Markets, "Leading Nanotechnology Companies Shaping the Global Market" (Nanophase, Nanoco, Applied DNA, 180 Degree Capital, BASF, DuPont), 2025. https://www.researchandmarkets.com/articles/key-companies-in-nanotechnology
10. Nano-X Imaging Ltd., SEC Form 6-K, Q3 2025 results (~$3.4M quarterly revenue); Investorideas nanotechnology stock directory. https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001795251&type=6-K
11. Applied Materials, "2025 Annual Report." https://ir.appliedmaterials.com/
12. Lam Research, "Annual Reports and Proxy Information." https://investor.lamresearch.com/annual-reports-and-proxy
13. KLA Corporation, "Form 10-K for Fiscal Year 2025." https://ir.kla.com/sec-filings
14. Onto Innovation, "Form 10-K for Fiscal Year 2024." https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000704532&type=10-K
15. Bruker, "Atomic Force Microscopes for Materials Research." https://www.bruker.com/en/products-and-solutions/microscopes/materials-afm.html
16. Veeco Instruments, "SEC Filings / Annual Report." https://ir.veeco.com/financial-information/sec-filings
17. Tracxn, "Carbon Nanotubes — Market & Investment Trends" (U.S. funding ~$165M across ~31 firms; overseas producers; 15–25% price declines; Group14 $1.2B raise), 2025. https://tracxn.com/d/trending-business-models/startups-in-carbon-nanotubes
18. Forge Nano, "Forge Nano to List on NASDAQ through Merger with Archimedes Tech SPAC Partners II" (list expected H2 2026; verify before acting), 2026. https://ir.forgenano.com/news/
19. Sila Nanotechnologies, "About Sila" (silicon anode battery materials; venture/strategic backing), 2026. https://www.silanano.com/about-us
20. Nano-C, "About Us" (fullerenes, single-wall carbon nanotubes, electronic materials), 2026. https://www.nano-c.com/about
21. American Elements, "Our Company" (advanced-materials supplier and R&D), 2026. https://www.americanelements.com/company.html
22. National Institute of Standards and Technology, "Center for Nanoscale Science and Technology," 2026. https://www.nist.gov/cnst
23. National Science Foundation, "National Nanotechnology Coordinated / Quantum-Nanotechnology Infrastructure," 2026. https://www.nsf.gov/
24. National Nanotechnology Coordination Office, "Supplement to the President's 2025 Budget" (record $2.2 billion request across 12 agencies), 2024. https://www.nano.gov/2025BudgetSupplement/
25. National Law Review / NNCO, "NNI Publishes Supplement to the President's FY 2026 Budget Request" ($1.45 billion across 10 agencies), 2026. https://natlawreview.com/article/nni-publishes-supplement-presidents-fy-2026-budget-request
26. SkyQuest, "Nanotechnology Drug Delivery Market" (~$103.8 billion in 2024; third-party estimate), 2025. https://www.skyquestt.com/report/nanotechnology-drug-delivery-market
27. Fortune Business Insights, "Lipid Nanoparticles Market Size, Share, Growth Report," 2025. https://www.fortunebusinessinsights.com/lipid-nanoparticles-market-106960
28. National Nanotechnology Coordination Office, "Applications of Nanotechnology," 2026. https://www.nano.gov/about-nanotechnology/applications-nanotechnology
29. U.S. Environmental Protection Agency, "Control of Nanoscale Materials under TSCA"; Federal Register, "Chemical Substances When Manufactured or Processed as Nanoscale Materials; TSCA Reporting and Recordkeeping Requirements," 2017. https://www.epa.gov/reviewing-new-chemicals-under-toxic-substances-control-act-tsca/control-nanoscale-materials-under
30. U.S. Food and Drug Administration, "Considering Whether an FDA-Regulated Product Involves the Application of Nanotechnology," 2014. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considering-whether-fda-regulated-product-involves-application-nanotechnology
31. Occupational Safety and Health Administration, "Nanotechnology" (with NIOSH recommended exposure limits). https://www.osha.gov/nanotechnology
32. U.S. Bureau of Industry and Security, Export Administration Regulations — advanced-computing and semiconductor-manufacturing controls, 2024. https://www.bis.gov/